Tactics
Targeted Antibody Creation Toolbox for Intracellular Complex Specificity
A precision immunotherapy discovery platform that designs highly potent and specific, cross-reactivity-free TCRmimic antibodies against any intracellular antigen.
Disease specific peptide-HLA antigens
Peptide-HLA (pHLA) complexes are a class of antigens derived from intracellular proteins that are being presented on the cell surface of most tumors and autoimmune diseases. These complexes offer a vast but largely untapped target space for precision immunotherapy that have been out-of-reach by conventional immunotherapies.
We are developing highly specific and potent TCR-mimic (TCRm) antibodies that target these disease-specific complexes, opening new frontiers in immunotherapy.
The challenge of cross-reactivity
Increasing the affinity of TCRmimic (TCRm) antibodies enhances target binding. Yet it also raises the risk of off-target interactions, potentially leading to unwanted toxicity. Striking the right balance between affinity and specificity is critical—too low, and efficacy is compromised; too high, and cross-reactivity becomes a concern.
How to determine the right sweet spot to balance affinity versus specificity?
The right balance between affinity and specificity
With our TACTICS platform we can determine the optimal sweet spot for any pHLA target upfront by applying target specific thresholds for both affinity and specificity. This allows us to identify antibodies during the earliest stages of discovery campaigns that meet the right criteria to maximize potency while maintaining strict target selectivity for safer, more effective therapies.
Our unique capabilities in antibody display and machine learning
Using antibody display technologies and machine learning, we are now engineering specific TCRmimic Antibodies binding pre-defined peptide epitopes that are 100% disease specific. Knowing how to hit disease specific epitopes, we can de-risk any therapeutic program, opening the door the universe of disease antigens,
